admin

Axial spondyloarthritis (axSpA) is a debilitating autoimmune disease that affects many individuals around the world. Researchers have now reported the full 52-week results from the two parallel phase III trials of the interleukin-17 (IL-17) blocker bimekizumab in axSpA, revealing strong efficacy. However, the future of this promising drug in the U.S. market is uncertain. This
0 Comments
The commodities market is experiencing a significant shift, presenting a more favorable investment landscape according to Aaron Dunn, co-head of value equity and portfolio manager at Morgan Stanley Investment Management. In an interview with CNBC’s “Squawk Box Asia,” Dunn highlighted that we are at the “beginning of a longer-term commodity cycle.” This shift implies that
0 Comments